“…( 2 ) Over the past decade, clinical research has demonstrated that SWE and other ultrasound readouts (such as echogenicity, backscatter coefficient, and/or attenuation) are safe and effective at diagnosing a multitude of liver pathologies in humans, including steatosis, ( 3 ) fibrosis/cirrhosis, ( 4 ) and cancer, ( 5 ) and have greatly reduced the reliance on invasive biopsy. ( 6 ) While the integration of SWE, and corollary technologies such as transient elastography, in clinical practice has progressed at a robust pace, there has been a notable lack of adoption of these technologies in preclinical research, despite a growing list of publications demonstrating the feasibility of the approach in rodent models (mice ( 7 , 8 , 9 ) and rats ( 10 , 11 , 12 , 13 , 14 , 15 , 16 , 17 , 18 , 19 , 20 , 21 , 22 , 23 ) ) and relevancy of these models to human liver stiffness measurements. ( 24 ) Basic science laboratories still mostly rely on histology to assess hepatic injury and response to therapy, ( 25 , 26 , 27 , 28 ) which hampers longitudinal studies because it requires subject endpoints, thus increasing the individuals enrolled and costs.…”